SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is rallying as investors react to a strategic $14.2 billion deal to regain full ownership of its Ireland-based Fab 34, a move perceived as a major vote of confidence in the company's manufacturing and AI-driven growth trajectory. The community is actively debating the stock's future, with many interpreting the heavy capital reinvestment as a clear indicator that major new customer contracts are imminent.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is currently trending following news that it has secured FDA approval for VYKAT XR, the first therapy developed to treat hyperphagia in Prader-Willi syndrome. The community is actively discussing the stock's significant price momentum, debating the potential for a future acquisition by a larger pharmaceutical player, and evaluating the long-term commercial execution of this newly approved asset.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as the market reacts to the company's latest subscription price hikes, which analysts view as a strategic move to fund a massive content budget and solidify profitability. While some retail investors are voicing frustration over recurring cost increases, the community is heavily focused on the stock's relative strength and technical breakout potential, with many discussing its role as a hedge against broader market volatility.

“Buttcoin - The Next Bitcoin” is the memecoin version of Bitcoin. Launched on January 30, 2025, on Pump.fun, it’s a community-owned memecoin on Solana. The idea was inspired by a 4:20 minutes long YouTube video from 2013 called "The Next Bitcoin?" by James D. McMurray.

The Next Bitcoin

Investors are rallying behind this Solana-based meme coin as a satirical movement intended to mock established market structures, with community members actively comparing its long-term potential to industry giants. Discussions are currently dominated by enthusiasts promoting the token's cultural narrative and its goal of creating viral engagement within the broader crypto ecosystem.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

Neurocrine Biosciences is trending as the market reacts to the definitive agreement to acquire Soleno Therapeutics for $2.9 billion. Community sentiment is mixed, with active debate regarding whether the acquisition effectively addresses Neurocrine's need for pipeline growth or if the premium paid for the rare-disease asset signals a strategic overpay.

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Altria Group Inc.

Altria Group is seeing significant investor interest driven by a combination of resilient pricing power in its core smokeable business and ongoing momentum in its smoke-free portfolio, particularly with the growth of its on! nicotine pouches. The community is actively debating the company's long-term pivot from traditional cigarettes toward smoke-free alternatives, with many highlighting the stock's role as a classic, high-yield defensive play in a volatile market.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxis Precision Medicines is experiencing a significant surge in momentum as the company reports positive trial results for its essential tremor and epilepsy therapies, driving multiple analyst price target upgrades. While the community is debating the impact of a recent large-scale public offering, many investors remain bullish on the long-term potential of the company's CNS-focused pipeline.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is currently trending as shareholders analyze the strategic implications of parent company Centurium Capitals acquisition of Blue Bottle Coffee. While the community remains divided over potential conflicts of interest versus synergistic growth, investors are closely monitoring for signs of a long-anticipated U.S. exchange relisting and are actively debating the stock's future valuation amid shifting institutional ownership.

A2Z Cust2Mate Solutions Corp. is a technology company, which engages in the development and commercialization of retail smart cart solutions for large grocery stores and supermarkets. It operates through the Smart Carts and Precision Metal Parts segments. The Smart Carts segment offers retail automation solutions. Its platform enables seamless in-cart scanning and payment, allowing shoppers to bypass checkout lines while receiving real-time customized offers and product recommendations. The Precision Metal Parts segment includes the manufacturing and sale of precision metal parts. The company was founded by Joseph Bentsur on January 15, 2018 and is headquartered in Vancouver, Canada.

A2Z Cust2Mate Solutions Corp.

A2Z Smart Technologies Corp.

A2Z Smart Technologies is trending following a major five-year strategic agreement to deploy 4,000 smart shopping carts at Carrefour Israel, a move the community views as a significant model for global scalability. Investors are actively discussing the company's retail media expansion, potential for recurring revenue, and bullish technical setups, with many highlighting institutional interest from significant fund stakes as a vote of confidence in the stock's long-term growth trajectory.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is currently trending due to intense speculation surrounding a potential short squeeze, driven by extremely limited share availability for borrowing and surging borrow fees. The community is actively debating the stock's volatility, with many retail traders drawing comparisons to historical meme stock runs while critics emphasize the company's lack of revenue and potential for dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Carnival Corp. (CCL) rose nearly 0.4% pre-market on Tuesday after the company’s <a href="https://stocktwits.com/news-articles/markets/equity/ccl-stock-dips-after-earnings-retail-stays-bullish/c76dXtiR3B">Q3 earnings report</a> sparked mixed reactions.On Monday, the stock initially dropped more than 6% but pared some losses to close slightly in the red after a softer-than-expected forecast for current-quarter net yields and profits overshadowed a profit beat and record quarterly revenue, dampening market sentiment.Despite the cautious outlook, Carnival raised its full-year profit guidance for the third time this year and lifted its net yield forecast to 10.4%, up from 10.25%.Barclays raised its price target on Carnival to $26 from $25, representing about 40% upside from current levels, while maintaining an ‘Overweight’ rating.The brokerage noted that while the Q3 results didn’t meet all expectations, strong demand and positive commentary keep Carnival’s 2025 outlook intact.Morgan Stanley also adjusted its price target, raising it to $16.50 from $15, but stuck with an ‘Underweight’ rating.The brokerage increased its EPS forecasts for FY24, FY25, and FY26 but expressed concerns about Carnival’s asset-heavy model and high financial leverage, which could make it more vulnerable to a potential slowdown compared to other travel names.Carnival has made progress on reducing its pandemic-era debt, which ballooned from $11.5 billion in 2019 to $34.5 billion in 2022. Since then, the company has reduced its debt by $5 billion.But on Monday, CEO Josh Weinstein expressed confidence in the company’s future, pointing to “enhanced commercial execution” and strong booking momentum, positioning Carnival for a solid 2025 and beyond.<figure class="image"><a href="https://stocktwits.com/symbol/CCL"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CCL_sentiment_and_message_volume_Oct_1_f412f043e2.png" alt="CCL sentiment and message volume Oct 1.png" width="1314" height="320"></a><figcaption>CCL sentiment and message volume Oct 1 pre-market</figcaption></figure>On Stocktwits, retail sentiment surged to ‘extremely bullish’ (95/100) levels, nearing the highest point this year, with a 36% spike in message volume.One user commented on the bullish outlook, noting the stock’s recovery and positive future trend.<stembedurl>https://stocktwits.com/Davruns/message/587589067</stembedurl>Another user looked ahead to a higher target price.<stembedurl>https://stocktwits.com/2023andbeyond/message/587617901</stembedurl>Shares of Carnival are up over 6% year-to-date, as of Monday’s close, compared to Norwegian Cruise Line’s (NCLH) 12% gain and Royal Caribbean’s (RCL) 47% surge. &nbsp;

Barclays raised its price target on Carnival to $26 from $25, representing about 40% upside from current levels.

Carnival Gets Price-Target Hikes After Q3 Earnings: Stock Rises, Retail Sentiment Near Year’s High

Barclays noted that while the Q3 results didn’t meet all expectations, strong demand and positive commentary keep Carnival’s 2025 outlook intact.

Equity

Beverage and coffeemaker conglomerate Keurig Dr Pepper announced its second-quarter results on Thursday with most metrics aligning with analyst estimates. Diluted earnings per share (EPS) came in at $0.45 while revenue stood at $3.92 billion, both in line with analyst estimates. Shares of the company traded over 2% higher on the news, with Stocktwits sentiment reaching a bullish zone (67/100) supported by extremely high message volume.<figure class="image"><img style="aspect-ratio:1582/448;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_25_at_1_32_22_PM_79a80ac8a7.png" alt="Retail sentiment trends in bullish territory for Keurig Dr Pepper" width="1582" height="448"><figcaption>Retail sentiment trends in bullish territory for Keurig Dr Pepper</figcaption></figure>During the second quarter, adjusted operating income rose 11% to $970 million led by higher net price realization and net productivity. Operating margin stood at 24.70% for the period. Meanwhile, adjusted net income rose 3.20% year-over-year (YoY) to $618 million.According to a CNBC report that cited Beverage Digest, Dr. Pepper recently surpassed Pepsi as the second-most consumed soda in the country.From a segment perspective, the US refreshment beverages net sales grew 3.30% to $2.40 billion driven by net price realization of 2.90%. Adjusted operating income rose 11.90% to $723 million with a healthy operating margin of 30%. However, the US Coffee segment witnessed a 2.10% decline in its net sales to $1 billion. International net sales rose 15.50% to $0.6 billion.CEO Tim Cofer stated that strong execution drove the company’s performance in the second quarter. “Now halfway through 2024, we are on track to achieve our unchanged full year outlook, while also seeding initiatives to fuel consistent growth over multiple years,” he said.The company reaffirmed its fiscal 2024 guidance for constant currency net sales growth in a mid-single-digit range, also projecting adjusted diluted EPS growth in a high-single-digit range.The year hasn’t been great for Keurig Dr Pepper stock with the shares basically flat YTD. Still, retail investors are betting on a rebound, citing pricing power and volume growth its competitors have been unable to achieve.One Stocktwits user named ‘Morechumanthanhuman’ expressed bullishness on the stock and stated that shares of the beverage-maker could move back to 40 on the back of these results.<figure class="image"><a href="https://stocktwits.com/Morechumanthanhuman/message/580656707"><img style="aspect-ratio:1534/454;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_25_at_1_33_31_PM_c38eeee921.png" alt="Stocktwits user Morechumanthanhuman's post on Keurig Dr Pepper" width="1534" height="454"></a><figcaption>Stocktwits user Morechumanthanhuman's post on Keurig Dr Pepper</figcaption></figure> Photo Courtesy: Brandon Richardson on Pexels

Keurig Dr Pepper Quenches Retail Investors’ Thirst For Earnings

The beverage-maker’s second quarter results were in line with analyst estimates, but retail investors are optimistic about management’s execution in a challenging retail consumer environment.

Neuberger Berman ETF Trust - Neuberger Berman Next Generation Connected Consumer ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

NBCC
Neuberger Berman ETF Trust - Neuberger Berman Next Generation Connected Consumer ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest NBCC News

NBCCNeuberger Berman ETF Trust - Neuberger Berman Next Generation Connected Consumer ETF